Skip to main content
ASTRO 2024 Main banner
Icon Legend
Presentation Icons
Event Add-on
Event Add-on
In Person Only
In Person Only
Off-site Event
Off-site Event
Location: Marriott Marquis
Location: Marriott Marquis
Back
Evaluation Watch onDemand

Gastrointestinal Cancer
Session Type: Scientific

SS 44 - GI 3: Pancreatic and Hepatibiliary: All About that Dose, 'bout that Dose, and ALBI

Wednesday, October 2, 2024
10:30 AM – 11:45 AM ET
Location: Room 144

AMA PRA Category 1 Credits 1.25

CAMPEP Credits: 1.25

MDCB Credits: 1.25

Presentations:

  • 10:30 AM – 10:40 AM ET
    Multi-Institutional Comparison of Ablative 5-Fraction MR-Guided Online Adapted vs. 15/25-Fraction CT-Guided Offline Adapted Radiation Therapy for Locally Advanced Pancreas Cancer

    Presenter: Michael Chuong, MD – Miami Cancer Institute

  • 10:40 AM – 10:50 AM ET
    The Effect of Tumor Biological Effective Dose (BED) on Stereotactic Body Radiotherapy (SBRT) Outcomes for Locally Advanced Cholangiocarcinoma (CCA): An Analysis of the ABC-07 Randomized Trial

    Presenter: Maria Hawkins, MD – University College London

  • 10:50 AM – 11:00 AM ET
    Safety and Efficacy Results of a Phase II Clinical Trial Evaluating Moderately-Hypofractionated Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma

    Presenter: Kenneth Merrell, MD, MS – Mayo Clinic Alix School of Medicine

  • 11:00 AM – 11:10 AM ET
    Discussant

    Discussant: Parag Parikh, MD, BSE – Henry Ford Hospital

  • 11:10 AM – 11:20 AM ET
    NRG Oncology International Consensus Atlas on Target Volumes for Dose-Escalated Pancreatic Cancer Radiotherapy

    Presenter: Nina Sanford, MD – UT Southwestern Medical Center

  • 11:20 AM – 11:30 AM ET
    Survival Prediction with Albumin-Bilirubin (ALBI) Changes in Hepatocellular Carcinoma Patients Treated with External Beam Radiotherapy (EBRT)

    Presenter: Smith Apisarnthanarax, MD – University of Washington

  • 11:30 AM – 11:40 AM ET
    Discussant

    Discussant: Kimberly Johung, MD, PhD – Yale University School of Medicine